Drug discovery

Auto Added by WPeMatico

Regina Barzilay and Jim Collins win Pritzker Prize for AI and Science Research Excellence for work in AI-enabled antibiotic discovery

ai, AI (Artificial Intelligence), Antibiotics, Artificial Intelligence, Awards, honors and fellowships, Bacteria, Biological engineering, Collaboration, Computer Science and Artificial Intelligence Laboratory (CSAIL), Computer science and technology, Disease, Drug discovery, Electrical engineering and computer science (EECS), Faculty, Harvard-MIT Health Sciences and Technology, Health sciences and technology, Institute for Medical Engineering and Science (IMES), Jameel Clinic, Koch Institute, Medicine, Microbes, MIT Schwarzman College of Computing, School of Engineering

Regina Barzilay, MIT’s School of Engineering Distinguished Professor of AI and Health, and James Collins, MIT’s Termeer Professor of Medical Engineering and Science, are the recipients of the 2026 Pritzker Prize for AI in Science Research Excellence. The award recognizes their joint work in “pioneering AI-enabled antibiotic discovery, integrating deep learning, bioengineering, and experimental validation to

Regina Barzilay and Jim Collins win Pritzker Prize for AI and Science Research Excellence for work in AI-enabled antibiotic discovery Read More »

Banner for AI & Big Data Expo by TechEx events.

Novo Nordisk and AWS bring agentic AI into drug discovery

agentic ai, ai, AI (Artificial Intelligence), AI in Action, Artificial Intelligence, aws, cloud infrastructure, Drug discovery, Features, Healthcare & Wellness AI, Healthcare AI, Human-AI Relationships, World of Work

Novo Nordisk is expanding its use of AWS artificial intelligence tools across drug discovery, including AI agents for target identification, therapy design, and research workflows. Under the agreement announced recently, AWS will become Novo Nordisk’s preferred cloud provider and strategic AI partner. The companies have also created a co-innovation hub at Novo Nordisk’s existing London

Novo Nordisk and AWS bring agentic AI into drug discovery Read More »

Why biological data matters more in AI drug discovery

ai, AI (Artificial Intelligence), AI in Action, Artificial Intelligence, data analysis, Deep Dives, Drug discovery, Healthcare & Wellness AI, Healthcare AI, How It Works, Human-AI Relationships, Machine Learning, wellness

GSK has entered into a research collaboration with British biotechnology company Relation Therapeutics worth up to $110 million, expanding the companies’ existing work in AI-assisted drug discovery. Under the agreement, Relation will generate large-scale datasets measuring how human cells respond to genetic changes and drug interventions. The data will be used to train AI models

Why biological data matters more in AI drug discovery Read More »

How AI is shortening drug discovery timelines in China

ai, AI (Artificial Intelligence), AI Business Strategy, AI in Action, Artificial Intelligence, business strategy, china ai, Drug discovery, Healthcare & Wellness AI, Healthcare AI, wellness, World of Work

Insilico Medicine has reduced the time needed to produce some drug development candidates to about one year by combining artificial intelligence with laboratory research in China, according to CEO Alex Zhavoronkov. The Hong Kong-listed company’s fastest programme reached candidate nomination in nine months, while its typical timeline is about 13 months, Zhavoronkov said. He said

How AI is shortening drug discovery timelines in China Read More »

Takeda signs US$600M AI drug discovery deal with Insilico

ai, AI (Artificial Intelligence), AI Business Strategy, AI in Action, AI Market Trends, Artificial Intelligence, business strategy, Drug discovery, Features, Healthcare, Healthcare & Wellness AI, manufacturing

Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas. The companies did not disclose which therapeutic areas or disease targets will be covered under the collaboration. The agreement gives Takeda access to Insilico’s Pharma.AI platform, which supports biological target

Takeda signs US$600M AI drug discovery deal with Insilico Read More »

Building AI models that understand chemical principles

ai, AI (Artificial Intelligence), Alumni/ae, Artificial Intelligence, Chemical engineering, Chemistry, Computer science and technology, Drug discovery, Electrical engineering and computer science (EECS), Faculty, Machine Learning, MIT Schwarzman College of Computing, Profile, School of Engineering

Among all of the possible chemical compounds, it’s estimated that between 1020 and 1060 may hold potential as small-molecule drugs.Evaluating each of those compounds experimentally would be far too time-consuming for chemists. So, in recent years, researchers have begun using artificial intelligence to help identify compounds that could make good drug candidates. One of those researchers is MIT

Building AI models that understand chemical principles Read More »

AI maps how a new antibiotic targets gut bacteria

Algorithms, Antibiotics, Artificial Intelligence, Bacteria, Computer Science and Artificial Intelligence Laboratory (CSAIL), Computer science and technology, Disease, Drug development, Drug discovery, Electrical engineering and computer science (EECS), Health care, Health sciences and technology, Jameel Clinic, Machine Learning, Medicine, MIT Schwarzman College of Computing, Research, School of Engineering, Viruses

For patients with inflammatory bowel disease, antibiotics can be a double-edged sword. The broad-spectrum drugs often prescribed for gut flare-ups can kill helpful microbes alongside harmful ones, sometimes worsening symptoms over time. When fighting gut inflammation, you don’t always want to bring a sledgehammer to a knife fight.Researchers at MIT’s Computer Science and Artificial Intelligence

AI maps how a new antibiotic targets gut bacteria Read More »